Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies

Abstract

Gastroesophageal malignancies often contain high amounts of genetic and molecular alterations that result in an aggressive disease capable of rapidly metastasizing to distant organs and early development of drug resistance. Most patients in the Western hemisphere present with locally advanced or metastatic disease that is treated with systemic chemotherapy used either in the neoadjuvant or palliative setting, respectively. This article will review the various recent advances in the development of targeted therapies for the treatment of advanced gastric and gastroesophageal cancer.

Keywords: Gastric adenocarcinoma; Gastric cancer; Gastroesophageal adenocarcinoma.